Analysts: Neurocrine Biosciences Inc (NBIX) Stock Could Go to $96

By Tina Gumbley
April 15, 2016

Neurocrine Biosciences Inc. (NBIX) is in analysts’ crosshairs after showing no change in  percent versus prior close. Wall Street analysts have favorable assessment of the stock, with a mean rating of 1.7. The stock is rated as buy by 3 analysts, with 6 outperform and 0 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 8 analysts offering adjusted EPS forecast have a consensus estimate of $-0.29 a share, which would compare with $-0.01 in the same quarter last year. They have a high estimate of $-0.21 and a low estimate of $-0.42. Revenue for the period is expected to total nearly $15.43M from $19.77M the year-ago period.

For the full year, 8 Wall Street analysts forecast this company would deliver earnings of $-1.95 per share, with a high estimate of $-1.82 and a low estimate of $-2.08. It had reported earnings per share of $-1.95 in the corresponding quarter of the previous year.

Revenue for the period is expected to total nearly $16.15M versus 19.77M in the preceding year.

The analysts project the company to maintain annual growth of around -9.18 percent over the next five years as compared to an average growth rate of 27.46 percent expected for its competitors in the same industry.

Among the 7 analysts Thomson/First Call tracks, the 12-month average price target for NBIX is $68.14 but some analysts are projecting the price to go as high as $96. If the optimistic analysts are correct, that represents a 105 percent upside potential from the recent closing price of $46.86. Some sell-side analysts, particularly the bearish ones, have called for $57 price targets on shares of Neurocrine Biosciences Inc..

In the last reported results, the company reported earnings of $-0.34 per share, while analysts were calling for share earnings of $-0.32. It was an earnings surprise of -6.3 percent. In the matter of earnings surprises, the term Cockroach Effect is often implied.

Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage include elagolix, which is in Phase III study for endometriosis and uterine fibroids; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for tardive dyskinesia, as well as in Phase II study for tourette syndrome; and NBI-640756, which is in Phase I study for essential tremor. Its research programs comprise Corticotropin-Releasing Factor Receptor1 Antagonist for congenital adrenal hyperplasia; VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize valbenazine for movement disorders in Japan and other Asian markets; The Mount Sinai School of Medicine of the City University of New York to develop and commercialize licensed products worldwide; and Dainippon Sumitomo Pharma Co. Ltd.

Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Originally published by CWRUObserver.com